Pregnancies for patients on dialysis are high risk and care by a multidisciplinary team is extremely important for a successful birth, explained Silvi Shah, MD, MS, FASN, assistant professor, Division of Nephrology and Hypertension, University of Cincinnati.
Patients on dialysis who are pregnant should be treated by a nephrologist, a maternal-fetal specialist, and a neonatologist due to the high-risk nature of the pregnancy, said Silvi Shah, MD, MS, FASN, assistant professor, Division of Nephrology and Hypertension, University of Cincinnati.
Transcript
What are some of the steps that can be taken to treat and monitor pregnant individuals on dialysis and improve the odds of a successful pregnancy?
One of the things is care by a multidisciplinary team is extremely, extremely important. They should be followed by a nephrologist or a kidney doctor. They should have maternal-fetal medicine, which is a high-risk obstetrician, and at the same time, they will likely need neonatology care, as well, because most of the babies who are born are low birth weights and are preterm. So, we really stress all these pregnancies to be monitored in a tertiary care center, which has a level 3 NICU [neonatal intensive care unit] there. So multidisciplinary care is extremely, extremely important to have successful outcomes.
Following delivery, how should treatment be adjusted and are there any postpartum complications that patients should be monitored for?
I think treatment after delivery, we just have to monitor both the mother and the baby very closely. Breastfeeding is safe, postpartum, if they are not on any medications, which can be teratogenic. It is usually encouraged in these women. We also have to make sure their blood pressure is under good control. If they had any history of preeclampsia or hypertension during pregnancy, we will have to monitor their blood pressure to make sure that is under good control.
MINT Trial 26-Week Data Show Inebilizumab for gMG Is Effective and Safe
April 1st 2025These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be presented in a late-breaking oral session at the upcoming American Academy of Neurology Annual Meeting.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Understanding Primary and Secondary Nonadherence to Chronic Oral Medication
March 28th 2025Medication nonadherence to oral anticoagulants and oral anti–prostate cancer medication has been scrutinized through new research conducted among patients and health care providers and presented by the American Medical Group Association at its 2025 annual meeting, held March 26-29 in Grapevine, Texas.
Read More